Globus Medical, Inc. shines with strong Q4 results & Nevro acquisition, boosting its market position. Click here to find out ...

Globus Medical currently trades at $75.69 per share and has shown little upside over the past six months, posting a middling ...

NuVasive infringed five patents from a spine surgeon, a jury determined, according to an April 22 report from Bloomberg Law. The jury ruled that screw assemblies from the Reline, Armada and VuePoint ...

a spinal cord stimulator company, according to an April 3 news release. The acquisition expands Globus Medical’s reach in the musculoskeletal market and the opportunity to add to its product ...

In the assessment of 12-month price targets, analysts unveil insights for Globus Medical, presenting an average target of $90 ...

Globus Medical, Inc. (NYSE:GMED), a leading musculoskeletal technology company, will announce its financial results for the ...

Nevro’s comprehensive HFX™ spinal cord stimulation (SCS ... limitation success in convincing surgeons to use Globus Medical or Nevro products and the ability to attract and retain sales ...

Globus Medical GMED continues to gain from surging demand for its Musculoskeletal Solutions products ... instruments used in an expansive range of spinal, orthopedic and neurosurgical procedures.

Globus Medical Inc is a medical device company that develops and provides healthcare products and solutions ... devices and instruments used mostly for spinal and orthopedic procedures, and ...